Sovaldi Update: Compliance Less Than Perfect

In a study “Analysis of “Real World” Sovaldi Use and Discontinuation Rates” by CVS Health, researchers found that roughly 8% of patients who took Sovaldi to treat Hepatitis C discontinued the treatment regimen before its conclusion. During the clinical trials for Sovaldi, Gilead Sciences’“breakthrough therapy,” only 2% of patients discontinued therapy, raising questions about Sovaldi’s effectiveness in a real world patient population where patients are normally sicker, older, have more complications, and are not observed as carefully in comparison to a clinical trial.

Read More

Breakthrough Hepatitis C Drug and Its Controversial Cost

Hepatitis C is a liver disease that results from the Hepatitis C virus (HCV). Roughly 3.2 million individuals in the United States have chronic HCV infection and infection is most prevalent among individuals born from 1945-1965 with the majority of those individuals infected during the 1970s to 1980s when infection rates were at their highest. Approximately 15,000 lives are lost each year due to HCV infection.

Read More